Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. It is grouped under the following drug class(es): Overactive bladder agents. Its therapeutic use is listed as urological agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Uritos, Staybla and imidafenacinum. Its PubChem CID is 6433090.
Imidafenacin
| CAS No | 170105-16-5 |
|---|---|
| Molecular Formula | C20H21N3O |
| Molecular Weight | 319.4 g/mol |
| Synonyms | 4-(2-methylimidazol-1-yl)-2,2-diphenylbutanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.
The listed CAS number is 170105-16-5.
The listed molecular formula is C20H21N3O.
The listed molecular weight is 319.4 g/mol.
4-(2-methylimidazol-1-yl)-2,2-diphenylbutanamide.
The source lists Uritos, Staybla and imidafenacinum.